

## The Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 6) Regulations, 2021

<i>Made</i>	<i>21<sup>st</sup> September, 2021</i>
<i>Coming into operation</i>	<i>22<sup>nd</sup> September, 2021</i>
<i>Laid before the States</i>	<i>, 2021</i>

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990<sup>a</sup> and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004<sup>b</sup>, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

### Amendment to the 2004 Regulations.

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004<sup>c</sup> ("**the 2004 Regulations**") insert the entries set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings.

---

<sup>a</sup> Ordres en Conseil Vol. XXXII, p. 192; amended by Order in Council No. IX of 2003; No. II of 2011; No. IV of 2018; Recueil d'Ordonnances Tome XXVI, pp. 177 and 483; Ordinance Nos. XXII and XXVII of 2002; Nos. XXI and XXXIII of 2003; No. XLII of 2006; No. XLIII of 2007; No. XXII of 2015; Nos. IX and XLIV of 2016; and No. XVI of 2020.

<sup>b</sup> Ordinance No. XIII of 2004; amended by Ordinance No. XXXIV of 2013 and No. XXV of 2017.

<sup>c</sup> G.S.I. No. 9 of 2004; amended by G.S.I. No. 42 of 2004; Nos 18, 25 and 38 of 2005; Nos 12, 18, 26, 36 and 46 of 2006; Nos 3, 5, 6, 16, 17 and 32 of 2007; Nos 11, 23, 29, 31, 47, 50 and 76 of 2008; Nos 16, 35, 43, 47 and 56 of 2009; Nos 5, 32, 48, 88, 91 and 99 of 2010; Nos 5, 13, 19, 37, 38 and 52 of 2011; Nos 5, 25, 33 and 52 of 2012; Nos 5, 27, 35, 42, 68, 78 and 87 of 2013; Nos 8, 11, 16, 25, 57, 69 and 99 of 2014; Nos 9, 33 and 106 of 2015; Nos 10, 17, 25, 31 and 49 of 2016;

**Citation, commencement and extent.**

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 6) Regulations, 2021, and shall come into force on the 22<sup>nd</sup> day of September, 2021.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 21<sup>st</sup> day of September, 2021.

A handwritten signature in black ink, appearing to read 'A. H. Brouard', with a long horizontal line extending to the right.

A. H. BROUARD

President of the States Committee for Health & Social Care

For and on behalf of the Committee

SCHEDULE 1

Regulation 1

ENTRIES TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
1.7.1	Liver disorders and related conditions/Biliary disorders	Ursodeoxycholic acid, film-coated tablets 500mg.
2.2	Bleeding disorders	Emicizumab, solution for injection, 30mg/ml, 150mg/ml, Vials. (For Tertiary Centre recommendation and according to NHS Prescribing Criteria only).
4.3.4	Mental health disorders/Depression	Sertraline, oral suspension 100mg/5ml, 100ml. Drug Tariff Special Order. (dm+d browser).
8.8.1	Immune system disorders and transplantation	Tacrolimus, granules 200mcg, 1mg, 50 Sachets.
8.8.4	Hormone responsive malignancy/Antineoplastic drugs/Anti-androgens	Enzalutamide, film-coated tablets, 40mg, 80mg. (In accordance with NICE TA number 712 or any revision thereof only).
8.8.7	Targeted therapy responsive malignancy	Dacomitinib, film-coated tablets, 15mg, 30mg, 45mg. (In accordance with NICE TA number 595 or any revision thereof only).

## EXPLANATORY NOTE

*(This note is not part of the Regulations)*

These Regulations add drugs and dressings to the list of products that may be prescribed as pharmaceutical benefit.

These Regulations come into force on the 22<sup>nd</sup> September, 2021.